JP2002535285A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002535285A5 JP2002535285A5 JP2000594485A JP2000594485A JP2002535285A5 JP 2002535285 A5 JP2002535285 A5 JP 2002535285A5 JP 2000594485 A JP2000594485 A JP 2000594485A JP 2000594485 A JP2000594485 A JP 2000594485A JP 2002535285 A5 JP2002535285 A5 JP 2002535285A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- preparation
- pharmaceutical composition
- inhibiting
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000016605 B-Cell Activating Factor Human genes 0.000 description 13
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 13
- 210000003719 b-lymphocyte Anatomy 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 11
- 230000004663 cell proliferation Effects 0.000 description 7
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 6
- 201000001268 lymphoproliferative syndrome Diseases 0.000 description 6
- 230000016784 immunoglobulin production Effects 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000021766 negative regulation of B cell proliferation Effects 0.000 description 1
- 230000005401 negative regulation of immunoglobulin production Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11716999P | 1999-01-25 | 1999-01-25 | |
| US60/117,169 | 1999-01-25 | ||
| US14322899P | 1999-07-09 | 1999-07-09 | |
| US60/143,228 | 1999-07-09 | ||
| PCT/US2000/001788 WO2000043032A2 (en) | 1999-01-25 | 2000-01-25 | Baff, inhibitors thereof and their use in the modulation of b-cell response |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008303135A Division JP4955642B2 (ja) | 1999-01-25 | 2008-11-27 | 免疫応答におけるｂ細胞および免疫グロブリンの刺激および阻害における、ｂａｆｆ、関連するブロック剤およびそれらの使用 |
| JP2012077812A Division JP2012126749A (ja) | 1999-01-25 | 2012-03-29 | 免疫応答におけるｂ細胞および免疫グロブリンの刺激および阻害における、ｂａｆｆ、関連するブロック剤およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002535285A JP2002535285A (ja) | 2002-10-22 |
| JP2002535285A5 true JP2002535285A5 (enExample) | 2009-01-22 |
| JP5066314B2 JP5066314B2 (ja) | 2012-11-07 |
Family
ID=26815006
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000594485A Expired - Lifetime JP5066314B2 (ja) | 1999-01-25 | 2000-01-25 | 免疫応答におけるｂ細胞および免疫グロブリンの刺激および阻害における、ｂａｆｆ、関連するブロック剤およびそれらの使用 |
| JP2008303135A Expired - Fee Related JP4955642B2 (ja) | 1999-01-25 | 2008-11-27 | 免疫応答におけるｂ細胞および免疫グロブリンの刺激および阻害における、ｂａｆｆ、関連するブロック剤およびそれらの使用 |
| JP2012012379A Withdrawn JP2012087145A (ja) | 1999-01-25 | 2012-01-24 | 免疫応答におけるｂ細胞および免疫グロブリンの刺激および阻害における、ｂａｆｆ、関連するブロック剤およびそれらの使用 |
| JP2012077812A Pending JP2012126749A (ja) | 1999-01-25 | 2012-03-29 | 免疫応答におけるｂ細胞および免疫グロブリンの刺激および阻害における、ｂａｆｆ、関連するブロック剤およびそれらの使用 |
| JP2014090152A Pending JP2014141527A (ja) | 1999-01-25 | 2014-04-24 | 免疫応答におけるｂ細胞および免疫グロブリンの刺激および阻害における、ｂａｆｆ、関連するブロック剤およびそれらの使用 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008303135A Expired - Fee Related JP4955642B2 (ja) | 1999-01-25 | 2008-11-27 | 免疫応答におけるｂ細胞および免疫グロブリンの刺激および阻害における、ｂａｆｆ、関連するブロック剤およびそれらの使用 |
| JP2012012379A Withdrawn JP2012087145A (ja) | 1999-01-25 | 2012-01-24 | 免疫応答におけるｂ細胞および免疫グロブリンの刺激および阻害における、ｂａｆｆ、関連するブロック剤およびそれらの使用 |
| JP2012077812A Pending JP2012126749A (ja) | 1999-01-25 | 2012-03-29 | 免疫応答におけるｂ細胞および免疫グロブリンの刺激および阻害における、ｂａｆｆ、関連するブロック剤およびそれらの使用 |
| JP2014090152A Pending JP2014141527A (ja) | 1999-01-25 | 2014-04-24 | 免疫応答におけるｂ細胞および免疫グロブリンの刺激および阻害における、ｂａｆｆ、関連するブロック剤およびそれらの使用 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6869605B2 (enExample) |
| EP (5) | EP2298332B1 (enExample) |
| JP (5) | JP5066314B2 (enExample) |
| KR (1) | KR100834809B1 (enExample) |
| CN (1) | CN100340292C (enExample) |
| AT (2) | ATE515267T1 (enExample) |
| AU (1) | AU762839B2 (enExample) |
| BR (1) | BR0007719A (enExample) |
| CA (1) | CA2360062A1 (enExample) |
| CY (2) | CY1107453T1 (enExample) |
| CZ (1) | CZ299819B6 (enExample) |
| DE (1) | DE60004635T2 (enExample) |
| DK (2) | DK1415659T3 (enExample) |
| EA (1) | EA006108B1 (enExample) |
| EE (1) | EE05699B1 (enExample) |
| ES (1) | ES2204528T3 (enExample) |
| HK (1) | HK1040628B (enExample) |
| HU (1) | HUP0105283A3 (enExample) |
| IL (3) | IL144202A0 (enExample) |
| IS (1) | IS5993A (enExample) |
| MX (1) | MXPA01007464A (enExample) |
| NO (2) | NO20013641L (enExample) |
| NZ (1) | NZ513284A (enExample) |
| PL (1) | PL198934B1 (enExample) |
| PT (2) | PT1146892E (enExample) |
| SI (1) | SI1146892T1 (enExample) |
| SK (1) | SK286665B6 (enExample) |
| TR (2) | TR200102147T2 (enExample) |
| WO (1) | WO2000043032A2 (enExample) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8212004B2 (en) | 1999-03-02 | 2012-07-03 | Human Genome Sciences, Inc. | Neutrokine-alpha fusion proteins |
| US20030175208A1 (en) * | 1996-10-25 | 2003-09-18 | Human Genome Sciences, Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
| US6689579B1 (en) | 1996-10-25 | 2004-02-10 | Human Genome Sciences, Inc. | Polynucleotides encoding neutrokine-α |
| US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
| EP0878552A1 (en) | 1997-05-13 | 1998-11-18 | Erasmus Universiteit Rotterdam | Molecular detection of chromosome aberrations |
| AU3516899A (en) | 1998-05-04 | 1999-11-23 | Dako A/S | Method and probes for the detection of chromosome aberrations |
| GB9828628D0 (en) | 1998-12-23 | 1999-02-17 | Glaxo Group Ltd | Novel ligand |
| US7833529B1 (en) | 1999-01-07 | 2010-11-16 | Zymogenetics, Inc. | Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor |
| US20050100548A1 (en) * | 2001-07-24 | 2005-05-12 | Biogen Idec Ma Inc. | BAFF, inhibitors thereof and their use in the modulation of B-cell response |
| US20030095967A1 (en) | 1999-01-25 | 2003-05-22 | Mackay Fabienne | BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders |
| CA2360062A1 (en) | 1999-01-25 | 2000-07-27 | Biogen, Inc. | Baff, inhibitors thereof and their use in the modulation of b-cell response |
| US6475987B1 (en) | 1999-05-06 | 2002-11-05 | National Jewish Medical And Research Center | Tall-1 receptor homologues |
| EP1210425B2 (en) | 1999-08-17 | 2015-06-17 | Biogen MA Inc. | Baff receptor (bcma), an immunoregulatory agent |
| UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| PT1255558E (pt) * | 2000-02-16 | 2006-11-30 | Genentech Inc | Anticorpos anti-april e células hibridoma |
| EP2275449B1 (en) | 2000-06-16 | 2016-09-28 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to BLyS |
| US7879328B2 (en) * | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
| US7220840B2 (en) | 2000-06-16 | 2007-05-22 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator protein |
| ATE451390T1 (de) * | 2000-08-18 | 2009-12-15 | Dyax Corp | Polypeptide zur bindung an das b-lymphozyten- stimulatorische protein (blys) |
| US20030091565A1 (en) | 2000-08-18 | 2003-05-15 | Beltzer James P. | Binding polypeptides and methods based thereon |
| UA83458C2 (uk) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
| ES2387546T3 (es) * | 2001-05-11 | 2012-09-25 | Amgen Inc. | Péptidos y moléculas relacionadas que se unen a TALL-1 |
| DK1436003T3 (da) | 2001-05-24 | 2010-03-15 | Zymogenetics Inc | TACI-immunoglobulin-fusionsproteiner |
| KR20040019105A (ko) * | 2001-08-03 | 2004-03-04 | 제넨테크, 인크. | ＴＡＣＩｓ 및 ＢＲ3 폴리펩티드 및 이의 용도 |
| AR035119A1 (es) | 2001-08-16 | 2004-04-14 | Lilly Co Eli | Anticuerpos humanos antagonistas anti-htnfsf13b |
| US7825089B2 (en) | 2001-10-24 | 2010-11-02 | National Jewish Health | Three-dimensional structures of TALL-1 and its cognate receptors and modified proteins and methods related thereto |
| US20080267965A1 (en) * | 2002-02-21 | 2008-10-30 | Kalled Susan L | Use of Bcma as an Immunoregulatory Agent |
| AU2003256836A1 (en) * | 2002-07-25 | 2004-02-16 | Genentech, Inc. | Taci antibodies and uses thereof |
| CN101899106A (zh) | 2002-10-29 | 2010-12-01 | 阿纳福公司 | 三聚细胞因子的三聚结合蛋白 |
| US7553930B2 (en) | 2003-01-06 | 2009-06-30 | Xencor, Inc. | BAFF variants and methods thereof |
| WO2004074511A1 (en) * | 2003-02-21 | 2004-09-02 | Garvan Institute Of Medical Research | Diagnosis and treatment of baff-mediated autoimmune diseases and cancer |
| EP1606312A2 (en) * | 2003-03-07 | 2005-12-21 | Xencor Inc. | Baff mutants with at least one amino acid substitution and methods of their production |
| AU2004233164B2 (en) | 2003-03-28 | 2009-10-08 | Biogen Ma Inc. | Truncated BAFF receptors |
| US20050163775A1 (en) * | 2003-06-05 | 2005-07-28 | Genentech, Inc. | Combination therapy for B cell disorders |
| EP2272868B1 (en) * | 2003-06-05 | 2015-03-04 | Genentech, Inc. | Combination therapy for B cell disorders |
| MXPA06004301A (es) | 2003-10-20 | 2006-06-05 | Biogen Idec Inc | Regimenes terapeuticos para antagonistas del factor de activacion de celulas b. |
| WO2005075511A1 (en) | 2004-01-29 | 2005-08-18 | Genentech, Inc. | Variants of the extracellular domain of bcma and uses thereof |
| US20080050381A1 (en) * | 2004-08-31 | 2008-02-28 | Tsutomu Takeuchi | Antihuman Baff Antibody |
| WO2006044582A2 (en) | 2004-10-13 | 2006-04-27 | The Washington University | Use of baff to treat sepsis |
| CA2596276A1 (en) * | 2005-01-28 | 2006-08-03 | Biogen Idec Ma Inc. | Use of baff to treat th2-mediated conditions |
| EP1844069A4 (en) * | 2005-01-28 | 2009-05-20 | Apollo Life Sciences Ltd | MOLECULES AND CHIMESE MOLECULES THEREOF |
| CA2609190A1 (en) * | 2005-05-18 | 2006-11-23 | Biogen Idec Inc. | Methods for treating fibrotic conditions |
| AU2006278227B2 (en) | 2005-08-09 | 2011-10-20 | Ares Trading S.A. | Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules |
| ZA200801354B (en) | 2005-08-09 | 2009-08-26 | Ares Trading Sa | Methods for treating B-cell malignancies using TACI-lg fusion molecule |
| US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| EA015860B1 (ru) * | 2005-10-13 | 2011-12-30 | Хьюман Дженом Сайенсиз, Инк. | Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа |
| CA2629306A1 (en) | 2005-11-23 | 2007-05-31 | Genentech, Inc. | Methods and compositions related to b cell assays |
| US8211649B2 (en) | 2006-03-31 | 2012-07-03 | Human Genome Sciences, Inc. | Methods of diagnosing and prognosing hodgkin's lymphoma |
| EA015342B1 (ru) | 2006-05-15 | 2011-06-30 | Арес Трейдинг С.А. | Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig |
| WO2010093993A2 (en) * | 2009-02-12 | 2010-08-19 | Human Genome Sciences, Inc. | Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance |
| BR112012022943A2 (pt) * | 2010-03-11 | 2018-06-05 | Gilead Connecticut Inc | inibidores de syk de imidazopiridnas |
| WO2013171296A1 (en) | 2012-05-16 | 2013-11-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Diagnostic and treatment of sarcoidosis |
| CZ2012561A3 (cs) * | 2012-08-22 | 2013-10-23 | Masarykova Univerzita | B-bunecný aktivující faktor pro zvýsení sliznicní imunity kojencu a prípravek jej obsahující |
| US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
| PH12022550138A1 (en) | 2013-03-13 | 2023-03-06 | Amgen Inc | Proteins specific for baff and b7rp1 and uses thereof |
| US9688767B2 (en) | 2013-03-15 | 2017-06-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method of predicting survival time in myocardial infarction patients by measuring BAFF levels |
| KR101493592B1 (ko) | 2013-04-29 | 2015-02-17 | 부산대학교 산학협력단 | Ｓｏｃｓ3 단백질을 이용한 ｂａｆｆ 연관 면역질환 치료제 스크리닝 방법 |
| EP3071024B1 (en) | 2013-11-19 | 2018-09-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized b-cell activating factor gene |
| TWI735853B (zh) | 2013-12-23 | 2021-08-11 | 美商克洛諾斯生技有限公司 | 脾酪胺酸激酶抑制劑 |
| US10435474B2 (en) | 2013-12-24 | 2019-10-08 | Ossianix, Inc. | Baff selective binding compounds and related methods |
| EA033604B1 (ru) | 2014-01-31 | 2019-11-08 | Boehringer Ingelheim Int | Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид |
| AR104368A1 (es) | 2015-04-03 | 2017-07-19 | Lilly Co Eli | Anticuerpos biespecíficos anti-cd20- / anti-baff |
| WO2016205714A1 (en) * | 2015-06-19 | 2016-12-22 | University Of Louisville Research Foundation, Inc. | Immunomodulation for the long term prevention and treatment of autoimmune diseases and foreign tissue rejection |
| CN107328620B (zh) * | 2017-06-23 | 2020-06-05 | 浙江普罗亭健康科技有限公司 | 用于流式细胞技术的封闭缓冲液及试剂盒 |
| WO2019126366A2 (en) * | 2017-12-19 | 2019-06-27 | The Johns Hopkins University | Baff therapy to promote anti- tumor immunity |
| US20210238295A1 (en) * | 2018-04-26 | 2021-08-05 | University Of Virginia Patent Foundation | Compositions and methods for treating abdominal aortic aneurysm |
| KR20210131372A (ko) | 2019-02-22 | 2021-11-02 | 크로노스 바이오, 인코포레이티드 | Syk 억제제로서의 축합된 피라진의 고체 형태 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| AU726486C (en) | 1996-03-14 | 2004-02-05 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
| US6541224B2 (en) | 1996-03-14 | 2003-04-01 | Human Genome Sciences, Inc. | Tumor necrosis factor delta polypeptides |
| BR9612752A (pt) * | 1996-10-25 | 2000-01-18 | Human Genome Sciences Inc | Neutrocina |
| SE9603950L (sv) | 1996-10-29 | 1997-10-27 | Bjoern Hellstroem | Klämskyddslist |
| WO1998027114A2 (en) * | 1996-12-17 | 1998-06-25 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| US5969102A (en) | 1997-03-03 | 1999-10-19 | St. Jude Children's Research Hospital | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
| CA2232743A1 (en) * | 1997-04-02 | 1998-10-02 | Smithkline Beecham Corporation | A tnf homologue, tl5 |
| WO1998055621A1 (en) | 1997-06-06 | 1998-12-10 | Regeneron Pharmaceuticals, Inc. | Ntn-2 member of tnf ligand family |
| AU743490B2 (en) * | 1997-06-06 | 2002-01-24 | Regeneron Pharmaceuticals, Inc. | NTN-2 member of TNF ligand family |
| AU9376498A (en) | 1997-09-05 | 1999-03-22 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
| EA005411B1 (ru) | 1997-09-12 | 2005-02-24 | Апотек Р Энд Д Са | Применение антитела против полипептида april для получения лекарственного препарата для лечения опухолей |
| EA200000311A1 (ru) | 1997-09-12 | 2000-10-30 | Апотек Р Энд Д Са | Новый белок иммунной системы - кау |
| WO1999026463A2 (en) | 1997-11-26 | 1999-06-03 | Eli Lilly And Company | Tnf ligand family gene |
| AU2093499A (en) | 1997-12-30 | 1999-07-19 | Chiron Corporation | Members of tnf and tnfr families |
| US6297367B1 (en) | 1997-12-30 | 2001-10-02 | Chiron Corporation | Polynucleotide encoding TNFL1 |
| AU1467000A (en) | 1998-11-04 | 2000-05-22 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | A novel tumor necrosis factor family member, drl, and related compositions and methods |
| GB9828628D0 (en) | 1998-12-23 | 1999-02-17 | Glaxo Group Ltd | Novel ligand |
| DE60005135T3 (de) | 1999-01-07 | 2015-04-09 | Zymogenetics, Inc. | Lösliche rezeptoren br43x2 und verfahren zu deren therapeutischen verwendung |
| CA2360062A1 (en) * | 1999-01-25 | 2000-07-27 | Biogen, Inc. | Baff, inhibitors thereof and their use in the modulation of b-cell response |
| US6475986B1 (en) | 1999-02-02 | 2002-11-05 | Research Development Foundation | Uses of THANK, a TNF homologue that activates apoptosis |
| CA2363112A1 (en) | 1999-02-23 | 2000-08-31 | Craig A. Rosen | Neutrokine-alpha and neutrokine-alpha splice variant |
| WO2000050633A1 (en) | 1999-02-24 | 2000-08-31 | The General Hospital Corporation | Method for cloning signal transduction intermediates |
| US6475987B1 (en) | 1999-05-06 | 2002-11-05 | National Jewish Medical And Research Center | Tall-1 receptor homologues |
| CA2399387C (en) * | 2000-02-11 | 2015-11-03 | Biogen, Inc. | Heterologous polypeptide of the tnf family |
| EP2275449B1 (en) | 2000-06-16 | 2016-09-28 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to BLyS |
| AU2001288260A1 (en) | 2000-08-15 | 2002-03-13 | Human Genome Sciences, Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
| EP1456347A4 (en) | 2001-11-16 | 2006-08-02 | Human Genome Sciences Inc | ANTIBODIES BINDING TO BLYS ACCORDING TO AN IMMUNOSPECIFIC MODE |
-
2000
- 2000-01-25 CA CA002360062A patent/CA2360062A1/en not_active Abandoned
- 2000-01-25 BR BR0007719-4A patent/BR0007719A/pt not_active Application Discontinuation
- 2000-01-25 DE DE60004635T patent/DE60004635T2/de not_active Expired - Fee Related
- 2000-01-25 EP EP10180420.1A patent/EP2298332B1/en not_active Expired - Lifetime
- 2000-01-25 PT PT00909970T patent/PT1146892E/pt unknown
- 2000-01-25 AT AT03018879T patent/ATE515267T1/de active
- 2000-01-25 HK HK02102203.7A patent/HK1040628B/en not_active IP Right Cessation
- 2000-01-25 ES ES00909970T patent/ES2204528T3/es not_active Expired - Lifetime
- 2000-01-25 IL IL14420200A patent/IL144202A0/xx unknown
- 2000-01-25 EP EP00909970A patent/EP1146892B1/en not_active Revoked
- 2000-01-25 SK SK1044-2001A patent/SK286665B6/sk not_active IP Right Cessation
- 2000-01-25 JP JP2000594485A patent/JP5066314B2/ja not_active Expired - Lifetime
- 2000-01-25 AU AU32142/00A patent/AU762839B2/en not_active Expired
- 2000-01-25 PL PL349772A patent/PL198934B1/pl unknown
- 2000-01-25 CN CNB008054878A patent/CN100340292C/zh not_active Expired - Lifetime
- 2000-01-25 EP EP10181337A patent/EP2319527A3/en not_active Ceased
- 2000-01-25 WO PCT/US2000/001788 patent/WO2000043032A2/en not_active Ceased
- 2000-01-25 EP EP15174329.1A patent/EP2974736A1/en not_active Withdrawn
- 2000-01-25 HU HU0105283A patent/HUP0105283A3/hu unknown
- 2000-01-25 TR TR2001/02147T patent/TR200102147T2/xx unknown
- 2000-01-25 EE EEP200100386A patent/EE05699B1/xx unknown
- 2000-01-25 DK DK03018879.1T patent/DK1415659T3/da active
- 2000-01-25 KR KR1020017009356A patent/KR100834809B1/ko not_active Expired - Lifetime
- 2000-01-25 DK DK00909970T patent/DK1146892T3/da active
- 2000-01-25 PT PT03018879T patent/PT1415659E/pt unknown
- 2000-01-25 EA EA200100822A patent/EA006108B1/ru not_active IP Right Cessation
- 2000-01-25 CZ CZ20012696A patent/CZ299819B6/cs not_active IP Right Cessation
- 2000-01-25 NZ NZ513284A patent/NZ513284A/en not_active IP Right Cessation
- 2000-01-25 EP EP03018879A patent/EP1415659B9/en not_active Revoked
- 2000-01-25 MX MXPA01007464A patent/MXPA01007464A/es active IP Right Grant
- 2000-01-25 AT AT00909970T patent/ATE247482T1/de active
- 2000-01-25 SI SI200030207T patent/SI1146892T1/xx unknown
-
2001
- 2001-01-25 TR TR2004/03498T patent/TR200403498T2/xx unknown
- 2001-07-06 IS IS5993A patent/IS5993A/is unknown
- 2001-07-09 IL IL144202A patent/IL144202A/en not_active IP Right Cessation
- 2001-07-24 NO NO20013641A patent/NO20013641L/no not_active Application Discontinuation
- 2001-07-24 US US09/911,777 patent/US6869605B2/en not_active Expired - Fee Related
-
2003
- 2003-11-14 CY CY20031101083T patent/CY1107453T1/el unknown
-
2008
- 2008-11-27 JP JP2008303135A patent/JP4955642B2/ja not_active Expired - Fee Related
-
2009
- 2009-08-20 IL IL200498A patent/IL200498A0/en unknown
-
2011
- 2011-10-05 CY CY20111100946T patent/CY1112458T1/el unknown
-
2012
- 2012-01-24 JP JP2012012379A patent/JP2012087145A/ja not_active Withdrawn
- 2012-03-29 JP JP2012077812A patent/JP2012126749A/ja active Pending
- 2012-04-27 NO NO20120524A patent/NO20120524A1/no not_active Application Discontinuation
-
2014
- 2014-04-24 JP JP2014090152A patent/JP2014141527A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002535285A5 (enExample) | ||
| Gridley et al. | Incidence of cancer among patients with rheumatoid arthritis | |
| HUS1600042I1 (hu) | Anti-CS1 antitestek terápiás alkalmazása | |
| JP2001515712A5 (enExample) | ||
| JP2003503361A5 (enExample) | ||
| WO2005102387A3 (en) | Therapeutic use of anti-cs1 antibodies | |
| ATE541860T1 (de) | Humane antikörper gegen cd40 zur therapie von b- zell tumoren | |
| JP2004501101A5 (enExample) | ||
| DE69709632D1 (de) | Humanisierte monoklonale anti-cd40 antikörper und fragmente zur hemmung der b-zellaktivierung | |
| JP2004523579A5 (enExample) | ||
| EP1245676A4 (en) | HUMANE MONOCLONAL ANTIBODIES AGAINST THE TGF-BETA II RECEPTOR AND THEIR MEDICAL USE | |
| WO2001078779A3 (en) | Antibody alpha4beta7 integrin and its use to treat inflammatory bowel disease | |
| ATE535255T1 (de) | Anti-tnf antikörper und methotrexat zur gleichzeitigen behandlung von autoimmunkrankheiten | |
| JP2020510039A5 (enExample) | ||
| JP2004537500A5 (enExample) | ||
| ATE407149T1 (de) | Detoxifizierung durch intramuskulär verabreichte f(ab')2 fragmente | |
| Marshall et al. | Effects of coumarin (1, 2-benzopyrone) and cimetidine on peripheral blood lymphocytes, natural killer cells, and monocytes in patients with advanced malignancies | |
| US6288074B1 (en) | Method of treating lymphoproliferative syndrome | |
| CN1062479C (zh) | 一种治疗前列腺疾病的药物及其制备方法 | |
| WO2002026193A3 (en) | Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas | |
| JPH11279199A5 (enExample) | ||
| Gilden et al. | Curcumin trial finds no activity | |
| Grin | Condylomata acuminata: Epidemiologie und Therapie. | |
| Nicoletti | Observations on Results Achieved in 25,000 Patients Treated with Both Acupuncture and Homeopathy | |
| RU2004121622A (ru) | Способ лечения субинволюции матки у коров |